Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke

Translational Stroke Research

Volumn 5, Issue 5, 2014, Pages 612-617

  Zhu, Wenbin ^a   Libal, Nicole L ^a   Casper, Amanda ^a   Bodhankar, Sheetal ^a,b   Offner, Halina ^a,b   Alkayed, Nabil J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

HLA DR2 transgenic mice; Immunotherapy; Ischemic stroke; Recombinant T cell receptor ligand; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; PEPTIDE DERIVATIVE; RTL 1000; T LYMPHOCYTE RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; HYBRID PROTEIN; NEUROPROTECTIVE AGENT; RTL1000 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL STROKE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; STANDARD; TRANSGENIC MOUSE; TREATMENT OUTCOME; ANIMAL; CEREBRAL ARTERY DISEASE; COMBINATION DRUG THERAPY; DISEASE MODEL; HUMAN; STROKE;

ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; NEUROPROTECTIVE AGENTS; RECOMBINANT FUSION PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84905582293     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-014-0348-8     Document Type: Article

References (32)

1. Fact sheet N 310. The top 10 causes of death. Media center of World Health Organization website. http://who. int/mediacentre/factsheets/fs310/en/index. html. Accessed July 2013.
2. Wang Y, Zhang Z, Chow N, et al. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke. 2012;43: 2444-9.
3. Offner H, Subramanian S, Parker SM, et al. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26: 654-65.
4. Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience. 2009;158: 1098-111.
5. Offner H, Subramanian S, Parker SM, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176: 6523-31.
6. Dirnagl U, Klehmet J, Braun JS, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38: 770-3.
7. Muir KW, Tyrrell P, Sattar N, Warburton E. Inflammation and ischemic stroke. Curr Opin Neurol. 2007;20: 334-42.
8. Gee JM, Kalil A, Shea C, et al. Lymphocytes: potential mediators of postischemic injury and neuroprotection. Stroke. 2007;38(2 Suppl): 783-8.
9. Nilupul Perera M, Ma HK, Arakawa S, et al. Inflammation following stroke. J Clin Neurosci. 2006;13: 1-8.
10. Burrows GG, Chang JW, Bachinger HP, et al. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999;12: 771-8.
11. Wang C, Mooney JL, Meza-Romero R, et al. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol. 2003;171: 1934-40.
12. Vandenbark AA, Rich C, Mooney J, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol. 2003;171: 127-33.
13. Dziennis S, Mader S, Akiyoshi K, et al. Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis. 2011;26: 123-33.
14. Subramanian S, Zhang B, Kosaka Y, et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke. 2009;40: 2539-45.
15. Gonzalez-Gay MA, Zanelli E, Khare SD, et al. Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice. Hum Immunol. 1996;50: 54-60.
16. Stroke therapy academic industry roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30: 2752-2758.
17. Albers GW, Goldstein LB, Hess DC, et al. Stroke Treatment Academic Industry Roundable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011;42: 2645-50.
18. Saver JL, Jovin TG, Smith WS, et al. Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices. Stroke. 2013;44: 3596-601.
19. Huan JY, Meza-Romero R, Mooney JL, et al. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J Chem Technol Biotechnol. 2005;80: 2-12.
20. Chang JW, Mechling DE, Bächinger HP, et al. Design, engineering and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2. J Biol Chem. 2001;276: 24170-6.
21. Zhu W, Wang L, Zhang L, et al. Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-dependent in male mice. Neuroscience. 2010;169: 758-69.
22. Zhang W, Davis CM, Edin ML, et al. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PLoS One. 2013;8(4): e61244.
23. Kilic E, Hermann DM, Hossmann KA. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport. 1999;10: 107-11.
24. Beerny-Lang MA, Hurst S, Tucker EI, et al. Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke. 2011;42: 1736-41.
25. Pham M, Kleinschnitz C, Helluy X, et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. Neuroimaging. 2010;49: 2907-14.
26. Momi S, Tantucci M, van Roy M, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013;121: 5088-97.
27. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol Lond. 2011;589: 4115-23.
28. Gauberti M, de Martinez LS, Orset C, et al. Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb Haemost. 2014;12: 409-14.
29. Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of tissue plasminogen activator (t-PA) and t-PA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated t-PA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96: 761-8.
30. Narita M, Bu G, Herz J, et al. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest. 1995;96: 1164-8.
31. Liebeskind DS. Recanalization and reperfusion in acute ischemic stroke. F1000 Med Rep. 2010; 2. pii: 71. doi: 10. 3410/M2-71.
32. Itakura A, Aslan JE, Sinha S, et al. Characterization of human platelet binding of recombinant T cell receptor ligand. J Neuroinflammation. 2010;7: 75. doi: 10. 1186/1742-2094-7-75.